| 1. |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| 2. |
李國立. 從日本《胃癌處理規約》修訂看胃癌治療發展趨勢. 中國實用外科雜志, 2019, 39(1): 75-78.
|
| 3. |
日本胃癌研究會. 胃癌取扱い規約. 第 11 版. 東京: 金原出版社, 1985: 14-27.
|
| 4. |
Tsujinaka T, Sasako M, Yamamoto S, et al. Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy (JCOG9501). Ann Surg Oncol, 2007, 14(2): 355-361.
|
| 5. |
日本胃癌研究會. 胃癌取扱い規約. 第 14 版. 東京: 金原出版社, 2010: 5-10.
|
| 6. |
Farran B, Müller S, Montenegro RC. Gastric cancer management: kinases as a target therapy. Clin Exp Pharmacol Physiol, 2017, 44(6): 613-622.
|
| 7. |
Laz?r DC, Avram MF, Romo?an I, et al. Prognostic significance of tumor immune microenvironment and immunotherapy: novel insights and future perspectives in gastric cancer. World J Gastroenterol, 2018, 24(32): 3583-3616.
|
| 8. |
李國立, 鮑陽, 李寧, 等. 以淋巴結轉移為主的晚期胃癌的 FLEP 法新輔助化療. 外科理論與實踐, 2005, 41(5): 425-428.
|
| 9. |
李國立, 鮑陽, 姜軍, 等. 動靜脈聯合給藥的 FLEOX 法新輔助化療加營養支持提高晚期胃癌的可切除率. 中華胃腸外科雜志, 2008, 11: 428-431.
|
| 10. |
李國立, 范朝剛, 鮑揚, 等. 動靜脈結合給藥的 FLEEOX 方案對以淋巴結轉移為主晚期胃癌的新輔助化療. 中華外科雜志, 2009, 47(15): 1171-1174.
|
| 11. |
Zhang C, Li G, Fan C, et al. Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer. World J Surg Oncol, 2012, 10: 162.
|
| 12. |
He Q, Li Y, Ma L, et al. Application of FLEEOX preoperative chemotherapy via intra-arterial and intravenous administration in treatment of unresectable locally advanced gastric cancer. J Gastrointest Surg, 2016, 20(8): 1421-1427.
|
| 13. |
He Q, Ma L, Li Y, et al. A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis. BMC Gastroenterol, 2016, 16: 8.
|
| 14. |
Yamada Y, Higuchi K, Nishikawa K, et al. Phase Ⅲ study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na?ve patients with advanced gastric cancer. Ann Oncol, 2015, 26(1): 141-148.
|
